NeutraKine® IL-17A Monoclonal antibody
NeutraKine® IL-17A Monoclonal Antibody for Neutralization, ELISA
Cat no : 69021-1-Ig
69021-1-Ig targets NeutraKine® IL-17A in Neutralization, Cell treatment, ELISA applications and shows reactivity with Human samples.
|Host / Isotype
|Mouse / IgG1
|human Humankine IL-17A protein HZ-1113
|Gene ID (NCBI)
|Protein A purification
|This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
|Stability and Storage
|Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.
This antibody can be used to neutralize the bioactivity of IL-17A.
Int J Chron Obstruct Pulmon Dis
IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD
Targeting mTOR with a sirolimus-eluting airway stent reduces pro-fibrotic TH17-cells and inhibits laryngotracheal stenosis